DMAE (Dimethylaminoethanol) vs Fasoracetam

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

DMAE (Dimethylaminoethanol)Fasoracetam
CategoryNootropicsNootropics
Standard Dose150-400 mg/day (as DMAE bitartrate, typically 37% DMAE)20-100 mg 1-3 times daily (sublingual or oral)
TimingMorning. With or without food.Morning and afternoon. Sublingual administration may provide faster onset and higher bioavailability. With or without food.
Cycle DurationOngoing; no strict cycling requiredCycles of 4-8 weeks on, 2-4 weeks off. Limited long-term safety data.
Evidence Levelanimal_plus_anecdotalanimal_plus_anecdotal

Mechanism

Structural analog of choline that crosses the BBB more readily than choline itself. Paradoxically increases choline availability not by serving as a direct precursor to acetylcholine, but by inhibiting choline metabolism in peripheral tissues, thereby increasing circulating choline available for brain uptake. Also acts as a free radical scavenger and membrane stabilizer. Reduces lipofuscin accumulation in neuronal cells, an age pigment associated with cellular aging.

Standard Dosing

150-400 mg/day (as DMAE bitartrate, typically 37% DMAE)

Timing

Morning. With or without food.

Cycle Duration

Ongoing; no strict cycling required

Side Effects

  • Headache
  • Insomnia
  • Muscle tension
  • Overstimulation
  • GI discomfort
  • Vivid dreams

Contraindications

  • Pregnancy (potential teratogenic effects — inhibits choline incorporation into phospholipids critical for fetal neural development)
  • Bipolar disorder (may worsen depressive phase)
  • Epilepsy (may lower seizure threshold)

Best Stacking Partners

RacetamsPhosphatidylserineOmega-3 (DHA)
B

Fasoracetam

Nootropics

Mechanism

Non-classical racetam that modulates all three groups of metabotropic glutamate receptors (mGluR Groups I, II, and III) and upregulates GABA-B receptors — a unique mechanism that distinguishes it from other racetams. Also enhances high-affinity choline uptake (HACU) and stimulates acetylcholine release. Does not significantly affect adrenergic, serotonergic, or dopaminergic receptors. The GABA-B upregulation is particularly notable as it may counteract GABA-B receptor downregulation caused by phenibut or baclofen tolerance.

Standard Dosing

20-100 mg 1-3 times daily (sublingual or oral)

Timing

Morning and afternoon. Sublingual administration may provide faster onset and higher bioavailability. With or without food.

Cycle Duration

Cycles of 4-8 weeks on, 2-4 weeks off. Limited long-term safety data.

Side Effects

  • Headache
  • Fatigue
  • GI discomfort
  • Irritability
  • Brain fog (paradoxical, at excessive doses)

Contraindications

  • Known hypersensitivity to racetams
  • Pregnancy and lactation (no safety data)
  • Severe renal or hepatic impairment

Best Stacking Partners

Alpha-GPCCDP-CholineAniracetamColuracetam

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →